Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed/refractory diffuse large B cell lymphoma

This review article highlights the proven efficacy of CD19-directed CAR T-cell therapy among patients with relapsed/refractory DLBCL, as well the myriad barriers preventing some eligible patients from receiving this novel treatment—including cost of therapy, patient hesitancy, and timely patient selection—and recommendations to overcome these barriers.